Who’s next? After Gilead snapped up Immunomedics for $21 billion in September, gaining access to Trodelvy, an antibody conjugate that could be used …
Stocks roared higher on Monday, but one legendary hedge fund manager isn’t breaking out the champagne just yet. Optimism that COVID-19’s spread may …
Written by Dan Cohen and Scott Matusow from Stockmatusow.com.
Synaptics Incorporated Top Oppenheimer analyst Andrew Uerkwitz has downgraded his rating on shares of Syros Pharmaceuticals Inc (NASDAQ:SYNA) to Sell – his first …